The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | Selecting between glofitamab and epcoritamab for elderly patients with R/R DLBCL
Swetha Thiruvengadam, MD, City of Hope, Duarte, CA, compares glofitamab and epcoritamab for elderly patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Prof. Thiruvengadam highlights the adverse events associated with each agent, as well as considering the route of administration when selecting between them. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think in terms of safety, you know, there isn’t significant differences, I would say, between the bispecifics. CRS occurred in, you know, 31% of the epco and 46% of the glofit, and ICANS occurred at any grade 24% of epco and 12% of the glofit patients. So overall I think we see both toxicities with both bispecifics. I think there are, you know, the one thing to consider is that glofitimab is time limited and epcoritamab is indefinite...
I think in terms of safety, you know, there isn’t significant differences, I would say, between the bispecifics. CRS occurred in, you know, 31% of the epco and 46% of the glofit, and ICANS occurred at any grade 24% of epco and 12% of the glofit patients. So overall I think we see both toxicities with both bispecifics. I think there are, you know, the one thing to consider is that glofitimab is time limited and epcoritamab is indefinite. So especially for elderly patients who may want to have some time period where they’re not getting treatment or quality of life is important. That may lead one to potentially select glofitimab compared to epcoritamab. So I think a lot of it, and then of course, the route of administration, epcor is subcutaneous, glofit is IV, so that may be considered as well with a patient discussion, which would be preferred. But I think overall, both drugs are safe in the elderly patients with no significant differences in terms of toxicity. But I think the duration of the treatment as well as mode of administration and just ease of what the provider is comfortable with may be factors that end up being used to decide which one to use for our patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Research funding: GNE, Genmab/Abbvie, ADC-T, Ipsen; Advisory Board/Consulting: Kite, Ipsen, Abbvie.
